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Atrial Fibrillation Clopidogrel Trial
with Irbesartan for prevention of
vascular events-active
Why is this study important and
noteworthy?
Atrial fibrillation is the most common cardiac
arrhythmia with a potential for serious adverse events like
stroke. The annual rate of stroke with AF is around 4.5% and
increases in patients older than 75 years of age. Warfarin has
long been established as the treatment of choice for stroke
prevention in patients with AF. However, there are several
issues with oral anticoagulation. Firstly, there is an increased
risk of haemorrhagic complications, secondly INR's
commonly fall out of range due to drug and food interactions
and require major lifestyle adjustment to accommodate
frequent testing. As a result investigators have tried to explore
options other than Warfarin to prevent cerebrovascular
events. Several studies have compared varying doses of
Aspirin to oral anticoagulation and a meta-analysis concluded
that Warfarin was superior in terms of preventing
cerebrovascular events but increased the risk of haemorrhage.
Clopidogrel added to aspirin had been found superior
to aspirin in some cardiology trials. Therefore the
investigators for ACTIVE also decided to explore whether
the combination of clopidogrel and aspirin was any match to
warfarin in patients with AF.
The trial had a third arm in which irbesartan which is
an ACE inhibitor was given to half the patients in a factorial
design, on the pretext that hypertension increases the risk of
stroke in patients with AF. The results of this trial are still
awaited.
Who were the participants?
ACTIVE included three separate interrelated trials.
ACTIVE W was an open label non-inferiority trial in which
clopidogrel plus ASA was compared to oral anticoagulation
in patients with AF and at least 1 risk factor for stroke.
ACTIVE A included patients with AF and at least 1 risk factor
for stroke who received ASA because they had a
contraindication to oral anticoagulation or because they were
unwilling to take an oral anticoagulant and half of them
received clopidogrel in a double blind placebo controlled
manner. ACTIVE I was a partial factorial, double-blind,
placebo-controlled trial of irbesartan in patients participating
in ACTIVE A or ACTIVE W.
The study was a multicenter trial performed at 580
centers in 33 countries. Patients were eligible if they had
ECG evidence of AF and at least one risk factor for stroke. If
they were less than 75 years of age, they had to have either
DM or CAD. They were excluded from ACTIVE A if they
had any contraindication to clopidogrel and from ACTIVE W
if they had contraindication to oral anticoagulation. ACTIVE
I is not described here as the results from it are still awaited.
What was the intervention?
In ACTIVE W, 3371 patients were assigned to oral
anticoagulation (keeping INR between 2 and 3) and 3335 to
a combination of Aspirin 75-100mg and Clopidogrel 75mg.
They were followed up for a median of 1.28 years.
ACTIVE A included patients who had had AF and
were at increased risk for stroke but were considered
unsuitable for oral anticoagulation. In ACTIVE A, 3772
patients were randomized to receive clopidogrel 75mg plus
aspirin 75-100mg and 3782 were assigned to placebo plus
aspirin 75-100mg. Both groups were followed up for a
median of 3.6 years.
What was the outcome?
In ACTIVE W there were 164 primary outcome
events (stroke, non-CNS systemic embolus, myocardial
infarction, or vascular death) on oral anticoagulation therapy
(annual risk 3.9%) compared with 234 events on clopidogrel
plus aspirin (annual risk 5.6%; relative risk [RR] 1.44, 95%
CI 1.18-1.76; p=0.0003).Oral anticoagulation was most
protective against stroke (RR 1.72, 95% CI 1.24-2.37;
p=0.001) and non-CNS systemic embolism (4.66, 1.58-13.8;
p=0.005). Rates of major haemorrhage were similar in the
two groups. However, total as well as minor bleeds were
significantly more common with clopidogrel plus aspirin than
with oral anticoagulation therapy (RR 1.21 and 1.23 and
p=0.001 and p=0.0009 respectively).
In ACTIVE A there were 832 primary outcome events
(stroke, MI, systemic embolism and death) in the aspirin plus
clopidogrel arm and 924 events in the aspirin plus placebo
arm (RR 0.89, p=0.01). The greatest benefit of the
combination was seen in stroke with a RR of 0.72 and
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p<0.001. However, the rate of major haemorrhage also
increased significantly with the combination. Therefore, on
combining the major vascular events and major
haemorrhages, the number of events in the two groups were
not significantly different (A+C 968 vs. A 996 events; p =
0.54). The addition of clopidogrel to aspirin reduced the rate
of major vascular events from 7.6% per year to 6.8%, but the
rate of haemorrhage increased from 1.3% to 2.0% per year. 
What were the conclusions?
ACTIVE W concluded that oral anticoagulation
therapy is superior to clopidogrel plus aspirin for prevention
of vascular events in patients with atrial fibrillation at high
risk of stroke who do not have contraindications to oral
anticoagulation therapy. The trial failed to show mortality
benefit with Warfarin. The number needed to be treated for 1
year with anticoagulation to prevent one stroke is about 100.
ACTIVE A concluded that a combination of aspirin
and clopidogrel is superior to aspirin alone for preventing all
vascular events and particularly strokes. However, this
advantage is offset by the risk of excess bleeding with the
combination.
How does this impact our clinical practice?
The clear advantage of oral anticoagulation for AF
was re-demonstrated in ACTIVE W. Therefore for patients
with AF at risk of stroke, and with no contraindications to
anticoagulation, Warfarin remains the drug of choice.
In our setting, putting patients on Warfarin is perhaps
a bigger challenge than it is in the West. Reasons for this
include lack of education regarding the drug, lack of proper
follow up, and sub standard medicines and laboratory testing.
For all these reasons, oral anticoagulation is often not
safe. For those with a clear cut contraindication to Warfarin,
a combination of aspirin and clopidogrel confers greater
protection against vascular events compared to aspirin alone.
However, given the increased risk of haemorrhage with the
combination, this decision should be based upon the absolute
risks of stroke and bleeding and the relative risk and benefit
for an individual patient.
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